Kura Oncology to Participate in Two Investor Conferences in November

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Kura Oncology (KURA) announced that management will present at two investor conferences on November 17 and 18, 2026.

The UBS Global Biopharma London Conference presentation is scheduled for November 17 at 1:20 p.m. GMT. The Jefferies Global Healthcare Conference presentation follows November 18 at 2:30 p.m. GMT. Live audio webcasts will be available through Kura’s investor website, with archived replays following the events.

Key Terms

menin inhibitor, farnesyl transferase inhibition

2 terms

menin inhibitor medical

"the FDA-approved once-daily, oral menin inhibitor"

A menin inhibitor is a type of experimental drug that blocks the action of a protein called menin, which some cancers use to keep growing. Think of it as flipping off a switch that cancer cells rely on to survive; by doing so, these drugs can slow or stop tumor growth. Investors watch menin inhibitors because clinical trial results, regulatory approvals, and market demand determine whether they become valuable cancer treatments and potential revenue drivers.

farnesyl transferase inhibition medical

"advancements in menin inhibition and farnesyl transferase inhibition"

Blocking the enzyme farnesyl transferase, which normally attaches a small lipid “farnesyl” tag to certain proteins so they can stick to cell membranes and send growth signals. Think of it like preventing a postage stamp from being added so a letter can’t be delivered to the right address. As a drug mechanism, it matters to investors because clinical trial outcomes, safety data, and regulatory decisions about these inhibitors can materially affect the value of companies developing them.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/13/2026 - 12:33 PM EST

SAN DIEGO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at the following investor conferences:

UBS Global Biopharma London Conference
November 17, 2026
1:20 p.m. GMT/ 8:20 a.m. ET / 5:20 a.m. PT

Jefferies Global Healthcare Conference
November 18, 2026
2:30 p.m. GMT/ 9:30 a.m. ET / 6:30 a.m. PT

Live audio webcasts will be available in the Investors section of Kura’s website at https://kuraoncology.com/, with archived replays available following the events.

About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI^® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.

Kura Contact

Investors and Media:
Greg Mann
gmann@kuraoncology.com